NeoGenomics, Inc. (NEO) Receives Average Rating of “Buy” from Brokerages
Shares of NeoGenomics, Inc. (NASDAQ:NEO) have been assigned a consensus recommendation of “Buy” from the ten analysts that are presently covering the firm, MarketBeat Ratings reports. Five investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $16.80.
Several analysts recently issued reports on the stock. Royal Bank of Canada set a $23.00 price target on shares of NeoGenomics and gave the stock an “outperform” rating in a research report on Wednesday. Scotiabank set a $22.00 price objective on shares of NeoGenomics and gave the company an “outperform” rating in a research note on Wednesday. CIBC set a $19.00 price objective on shares of NeoGenomics and gave the company a “neutral” rating in a research note on Wednesday. BidaskClub downgraded shares of NeoGenomics from a “buy” rating to a “hold” rating in a research note on Thursday, December 21st. Finally, Janney Montgomery Scott reaffirmed a “buy” rating on shares of NeoGenomics in a research note on Thursday, October 26th.
Shares of NeoGenomics (NEO) traded up $0.15 on Monday, reaching $8.73. 190,433 shares of the company were exchanged, compared to its average volume of 277,064. NeoGenomics has a twelve month low of $7.12 and a twelve month high of $11.63. The firm has a market cap of $689.91, a price-to-earnings ratio of -24.94, a P/E/G ratio of 3.46 and a beta of 0.84. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.99 and a current ratio of 2.14.
A number of large investors have recently bought and sold shares of NEO. GSA Capital Partners LLP bought a new position in NeoGenomics in the 3rd quarter worth $369,000. California Public Employees Retirement System grew its position in NeoGenomics by 12.7% during the 3rd quarter. California Public Employees Retirement System now owns 101,663 shares of the medical research company’s stock valued at $1,132,000 after purchasing an additional 11,463 shares during the last quarter. Granahan Investment Management Inc. MA grew its position in NeoGenomics by 5.3% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 1,065,082 shares of the medical research company’s stock valued at $11,854,000 after purchasing an additional 53,958 shares during the last quarter. Janus Henderson Group PLC grew its position in NeoGenomics by 50.3% during the 3rd quarter. Janus Henderson Group PLC now owns 3,464,655 shares of the medical research company’s stock valued at $38,562,000 after purchasing an additional 1,159,888 shares during the last quarter. Finally, PEAK6 Investments L.P. purchased a new stake in shares of NeoGenomics during the 3rd quarter valued at about $592,000. Institutional investors and hedge funds own 83.43% of the company’s stock.
TRADEMARK VIOLATION WARNING: “NeoGenomics, Inc. (NEO) Receives Average Rating of “Buy” from Brokerages” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.watchlistnews.com/neogenomics-inc-neo-receives-average-rating-of-buy-from-brokerages/1797603.html.
NeoGenomics Company Profile
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.